New Delhi: India has initiated a probe into alleged dumping of a pharma raw material, Ceftriaxone Sodium Sterile, from China, following complaints by domestic manufacturers.
Nectar Life Sciences and Sterile India have filed an application before the Commerce Ministry's investigation arm Directorate General of Trade Remedies (DGTR) seeking initiation of the probe.
According to a DGTR notification, the applicants have contended that material injury is being caused to the domestic industry due to dumped imports from China.
They requested imposition of anti-dumping duty on the import.
Ceftriaxone Sodium Sterile is an active pharmaceutical ingredient (API) or raw material used for formulation for treating disease like lower respiratory tract infection, skin infection, and intra-abdominal infection.
"On the basis of the duly substantiated written application by the domestic industry, and having satisfied itself, on the basis of the prima facie evidence submitted by the domestic industry, about dumping of the subject goods originating in or exported from the subject country (China)...the authority, hereby, initiates an investigation," it said.
In the probe, the directorate will determine the existence, degree and effect of alleged dumping in respect of the product from China.
Read more:Adani debunks GDP rhetoric, says India will be 2nd largest economy by 2050